Optimising Multispecific Antibody Design for Therapeutic Application
- By incorporating multifunctionality into a single molecule and leveraging novel mechanisms of biological activity, multispecific antibodies have the potential to provide modes of therapeutic intervention not feasible with traditional monoclonal antibodies or their combination
- Imperative to the design of multispecifics however is the optimal integration of each individual binding component within the multispecific structure to yield optimal biological activity, while maintaining desired pharmacological and manufacturing properties. The Azymetric platform, provides a convenient solution for generating efficient stable heterodimer antibody assembly to enable a multispecific platform adaptable to different formats supporting a range of applications
- Case studies covering examples of Azymetric based therapeutics will be shared ranging from Ziihera, approved for the treatment of HER2+ Billiary Tract cancer, to bispecific ADCs, to next generation T-cell engagers incorporating conditional costimulation applicable across solid and hematological cancers. Emphasis will be placed on the importance of matching format to desired biological activity and mode of therapeutic intervention to yield differentiated drug candidates.